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Abstract
Objective To determine whether 3D cone-beam computed
tomography (CBCT) guidance allows safe and accurate
biopsy of suspected small renal masses (SRM), especially
in hard-to-reach anatomical locations.
Materials and methods CBCT guidance was used to per-
form 41 stereotactic biopsy procedures of lesions that were
inaccessible for ultrasound guidance or CT guidance. In
CBCT guidance, a 3D-volume data set is acquired by rotat-
ing a C-arm flat-panel detector angiosystem around the
patient. In the data set, a needle trajectory is determined
and, after co-registration, a fusion image is created from
fluoroscopy and a slice from the data set, enabling the
needle to be positioned in real time.
Results Of the 41 lesions, 22 were malignant, 17 were
benign, and 2 were nondiagnostic. The two nondiagnostic
lesions proved to be renal cell carcinoma. There was no
growth during follow-up imaging of the benign lesions
(mean 29 months). This resulted in a sensitivity, specificity,
PPV, NPV, and accuracy of 91.7, 100, 100, 89.5, and 95.1%,
respectively. Mean dose-area product value was 44.0 Gy·cm2
(range 16.5–126.5). There was one minor bleeding
complication.
Conclusion With CBCT guidance, safe and accurate biopsy
of a suspected SRM is feasible, especially in hard-to-reach
locations of the kidney.
Key Points
• Cone-beam computed tomography has potential advan-
tages over conventional CT for interventional procedures.
• CBCT guidance incorporates 3D CBCT data, fluoroscopy,
and guidance software.
• In hard-to-reach renal masses, CBCT guidance offers an
alternative biopsy method.
• CBCT guidance offers good outcome and safety and has
potential clinical significance.
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Introduction
The classic but nonspecific symptoms of a renal tumor are
loin pain, hematuria, or a palpable mass. In this setting most
masses are malignant [1]. This classic triad is rare nowa-
days. Due to an increase in the use of high-quality abdom-
inal imaging for other, unrelated reasons there is an
increasing number of incidentally found renal masses. Many
of these masses are asymptomatic and small (<4 cm) renal
masses (SRMs). These SRMs tend to behave less aggres-
sively [2, 3]. Thompson et al. [4] found a relationship
between tumor size and malignancy. Larger masses have a
significantly higher ratio of malignancy. Marinez-Pineiro et
al. [5] pointed out the important role in the diagnostic and
therapeutic algorithm of biopsying small renal masses for
histopathological proof [4] because a substantial percentage
of SRMs are benign (13.0–46.3%). Some SRMs can be
diagnosed by imaging (e.g., fat in the lesion on CT indicat-
ing an angiomyolipoma), but many SRMs cannot be diag-
nosed based on the imaging alone. This will result in
increased indications for performing biopsies.
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A new real-time stereotactic needle guidance technique,
3D cone-beam computed tomography (CBCT) guidance,
uses a combination of cone-beam CT and real-time fluoros-
copy in the angiography suite [6, 7]. Lesions that cannot be
clearly identified on ultrasound (US) can be rendered visi-
ble. Compared with conventional computed tomography
(CT)-guided biopsy, CBCT guidance offers more sterile
workspace and better angulation/rotation ability because of
the C-arm configuration, making it easier to biopsy hard-to-
reach SRMs, especially in the upper pole and/or on the
anterior side of the kidney [7]. The objective of this study
is to determine the outcome of biopsying SRMs, especially
hard-to-reach lesions, in a prospective cohort of patients.
Materials and methods
This study was approved by the institutional review board.
Informed consent was obtained from all patients. Between
October 2006 and November 2009 we performed 43 proce-
dures in 43 patients using CBCT guidance. There were 28
men and 15 women, with a mean age of 61.9 years (range
35–81). The baseline data of the study population are shown
in Table 1. These patients had undergone abdominal imag-
ing for nonurogenital issues, during which a suspicious
renal mass was discovered as an incidental finding. Based
on the abdominal imaging, the lesions were not (easily)
accessible under CT guidance because of the anatomical
position of the lesion. Before referring these patients for
CBCT guidance, the patients were evaluated by ultrasound.
Only patients with lesions inaccessible under ultrasound
guidance (due to body habitus, mass location, invisibility
due to gas or bone, or interposition of other organs) were
included in this study. There was no target lesion size limit.
During CBCT guidance, patients had to be able to lie
reasonably still for a short period of time (approximately
30 min) and comply with breath-hold commands if needed.
Furthermore, patients with contraindications for percutane-
ous intervention (e.g., blood coagulation disorders) were
excluded.
Procedure
CBCT guidance uses a flat panel detector C-arm system
(XperCT® and XperGuide®, Allura FD20, Philips Health-
care, the Netherlands). A 3D volume data set is acquired
during a 240° rotation of the C-arm around the upper abdo-
men of the patient in 4–10 s. In six patients, intravenous
contrast (50 mL with 4 mL/s Xenetix® 300 mg/mL, Guer-
bet, the Netherlands; delay before data acquisition of 40 s)
was administered during the examination to discriminate the
mass from surrounding structures/parenchyma (Fig. 1). For
all other masses, no contrast administration was needed
because they were exophytic or had other discriminating
factors. The radiologist determines a safe needle trajectory
within the reconstructed data set, taking account of critical
anatomical structures (Fig. 2a, b). Using the information of
the planned needle trajectory, a fusion image of fluoroscopy
and the relevant double oblique slice of the cone-beam CT is
created in which the needle can be accurately positioned.
The patient is asked to breathe in until the diaphragm is in
the same position as the double oblique slice of the CBCT.
When the diaphragm on the fluoroscopy image matches the
CBCT slice during inspiration, the patient was given a
breath-hold command, and under real-time fluoroscopy the
needle is advanced over the predefined needle path to the
right depth (Fig. 2c) [6, 7]. The procedure is performed with
local anaesthesia. Sampling was done using a coaxial tech-
nique with a guiding cannula [Bard® TruGuide®;17 G; 13
or 17 cm (Bard Biopsy Systems, Tempe, AZ, USA)] posi-
tioned just proximal to the renal mass. Three to six 18 G
biopsies were then taken through the guiding needle to
obtain at least 1 cm of biopsy length. The Tru-Cut needle
(Bard® Magnum®;18 G; 16, 20 or 25 cm; side cutting, 15 or
22 mm) is loaded in an automated biopsy gun (Bard®).
After the needle intervention, a (collimated) control cone-
beam CT was always performed for checking needle posi-
tion accuracy and to check for possible complications
(Fig. 2d). The procedures were performed by an interven-
tional radiologist (M.S., >10 years of experience) and a
radiology resident (S.B., 5 years of experience), both with
equal experience in CBCT guidance. Local experience in
using this CBCT technique is now 3 years. After the proce-
dure, patients remained under observation in the hospital for
4 h. In case of significant changes in vital signs or clinical
status, repeat abdominal imaging was indicated (e.g., ultra-
sound or CT depending on the clinical condition of the
patient).
Data collection and analysis
All the radiological reports, histopathological data, and
medical records were collected for each procedure. The
result of a percutaneous renal mass biopsy was defined as
Table 1 The baseline data of the study population
Characteristic Value
Age (years), mean ± SD 62.0±11.3
Male/female (n) 26/15
Body mass index (kg/m2), mean ± SD 27.1±3.5
Diameter of lesion (mm), mean ± SD 25.0±7.6
Number of biopsies per procedure, mean ± SD 3.4±0.7
Lesion solid/cystic/both (n) 38/1/2
Procedure time (min), mean ± SD 29.2±10.7
Dose area product (Gy·cm2), mean ± SD 44.0±21.0
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true positive (TP) if the histopathological examination
revealed a renal cell carcinoma or a metastasis. A false
positive (FP) biopsy was defined as a biopsy showing ma-
lignancy, where there was no evidence of a malignancy
during surgery [in the absence of preoperative chemothera-
py of other (ablative) therapy]. If the histopathology showed
a benign result (e.g., normal renal parenchyma, infection,
infarction, or oncocytoma), the biopsy was considered true
negative (TN) if the renal mass proved to be benign during
surgical resection or if there was no suspicion of a malig-
nancy during follow-up imaging for at least 12 months [8].
If the final diagnosis during surgery showed malignancy and
the diagnosis based on the results of the biopsy procedure
was benign or nondiagnostic, the biopsy result was defined
as false negative (FN). Sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV), and
diagnostic accuracy were calculated. The dose-area product
(DAP) (Gy·cm2), which was obtained from the system, was
also registered for an indication of the radiation dose in-
volved. Data registration was performed using Excel
(Microsoft® Office Excel, Redmond, WA, USA). The out-
come was determined by using a 2×2 table.
Fig. 1a, b An 81-year-old man
with a suspected endophytic
kidney mass during abdominal
CT imaging. After biopsy, his-
topathological analysis revealed
a clear cell renal cell carcinoma.
Difference in cone-beam CT
(CBCT) without contrast medi-
um (a) and contrast-enhanced
CBCT (b). The endophytic re-
nal mass (white arrows) is only
visible on the contrast-
enhanced CBCT
Fig. 2a–d A 73-year-old man
with a suspected lesion at the
dorsal side of the upper pole of
the left kidney. Histopathologi-
cal analysis revealed a clear cell
renal cell carcinoma. Cone-
beam computed-tomography
(CBCT) guidance sequences
during a procedure. a After
obtaining a CBCT the radiolo-
gist determines in the axial
CBCT the desired needle tra-
jectory in the axial view
(avoiding the costae). b The
needle trajectory is adjusted by
the radiologist (white arrow) to
avoid essential organs (the dia-
phragm/lung). c Fusion image
of fluoroscopy and the double
oblique cone-beam CT slice
with the predefined needle tra-
jectory, making real-time accu-
rate needle placement possible.
d Control cone-beam CT image
(double oblique) with the guid-
ing cannula in place over the
predefined needle trajectory,




The sensitivity, specificity, PPV, NPV, and accuracy of CBCT
guidance in renal masses were 91.7, 100, 100, 89.5, and 95.1%,
respectively (Table 2). In 41 biopsies, 22 (53.7%) malignancies
were found: 10 clear cell renal cell carcinomas (RCCs), two
papillary RCCs, one chromophobe RCC, one eosinophilic
RCC, one sarcomatoid type RCC, four transitional cell carci-
nomas, two metastases of non-small-cell lung cancer, and one
B-cell lymphoma. All of these except the metastases and lym-
phoma were also surgically proven. During follow-up imaging
of these patients, no evidence of tumor seeding on the needle
track was seen. Seventeen (41.5%) biopsies, without rebiopsy-
ing, were classified as benign: four post-infectious changes,
three oncocytomas, six biopsies showing normal renal paren-
chyma, one organizing hematoma, one angiomyolipoma, one
inflammatory pseudotumor, and one infarction. The mean
follow-up of the benign lesions was 29 months (range 18–
45), without evidence of malignancy (e.g., lesion size growth).
Two (4.9%) were nondiagnostic biopsies.
The two patients with nondiagnostic lesions of 23.3 and
31 mm underwent (partial) nephrectomy because of suspi-
cious cells found during histopathological examination.
These masses proved to be RCC after surgical resection.
Twenty-two (53.7%) lesions were endophytic. Contrast
was used to visualize the lesion on CBCT in six patients
(14.6%). Detailed information on tumor location is shown in
Table 3. Mean diameter was 25.0 mm (range 10–40 mm),
and the mean number of biopsies per procedure was 3.4
(range 3–6). Mean DAP value was 44.0 Gy·cm2 [standard
deviation (SD) 21.0; range 16.5–126.5]. There were no
serious adverse events. In one patient (2.4%) a continuing
minor bleeding through the co-axial needle was present.
This was treated directly by injecting hemostatic material
(Spongostan®; Baxter, Deerfield IL, USA)]. No additional
intervention or prolonged hospital admission was required.
Discussion
CBCT guidance has a sensitivity of 91.7%, an NPV of
89.5%, and an accuracy of 95.1% for histopathological
biopsies of renal masses. To the authors’ knowledge, only
Kroeze et al. [9] has so far described CBCT guidance for
biopsy of renal masses. They reported a technical feasibility
of 77% in a small patient population (n013) [9]. We report a
better outcome, probably because of our larger population
and longer experience with CBCT guidance.
Volpe et al. [10] reviewed the technique, safety, and
accuracy of sampling of renal tumors by core biopsy using
CT or US and reported a sensitivity of 70–100%. In the
study performed by Rybicki et al. [11], a sensitivity of 90%
was reported. Several other studies have also evaluated the
sensitivity of renal biopsies, resulting in an overall sensitiv-
ity for diagnosis of malignancy of 80–95%. However the
studies show considerable variation in population and meth-
od of guidance (US or CT) [1, 12–14].
Vasudevan et al. [1] report 47 malignant biopsies, 23
benign biopsies, and 4 false negative biopsies resulting in
an NPVof 85.2%. Rybicki et al. [11] had an NPVof 64% in
their population. In our study population, the NPV was
89.5%.
Nadal et al. [12] described an accuracy of 87% on the
initial biopsy improving to 97% after a second biopsy.
Biopsies were performed using an 18 G core biopsy needle,
and an overall accuracy of 89% was achieved [15, 16].
Shannon et al. [17] reported a diagnostic biopsy rate of
78%, with 22% nondiagnostic biopsies due to insufficient
material or nonmalignant renal material. Our accuracy is in
the same range (95.1%).
Our results of the percutaneous renal biopsies using
CBCT guidance are comparable with those in the literature.
However in most of our procedures the needle trajectory had
to be at a (steep) double oblique angle, which is more
difficult to perform using CT(fluoroscopy) guidance. To
perform angulated procedures with CT guidance, there are
a couple of techniques available. One possibility is the
gantry tilting method, whereby the gantry of the CT system
is tilted between 0 and 30° depending on the vendor, making
an angulated biopsy possible. The tilting method proved to
be accurate (90–96%) in biopsy of hard-to-reach upper
abdominal masses [18]. The operator can, during the tilting
method, also use CT fluoroscopy, visualizing the slices of
interest in real time. A drawback of tilting is the negative
influence on the sterile workspace, which is already reduced
Table 2 Outcome of percutaneous biopsy of small renal masses using
3D cone-beam computed tomography (CBCT) guidance
CBCT guidance Renal mass Total
Malignant Benign
Malignant 22 0 22
Benign 2 17 19
Total 24 17 41
Table 3 Anatomical details of tumor location
Lower half Upper half Total
Dorsal 2 11 13
Lateral – 8 8
Medial – 5 5
Ventral 7 8 15
Total 9 32 41
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during conventional CT (fluoroscopy) guidance compared
to the C-arm configuration [19].
Another technique, which has a histopathological accuracy
of 76%, is the triangulation technique as described by van-
Sonnenberg et al. [20]. It requires calculation of the angle and
trigonometric tables. During the procedure a large number of
slices need to be scanned to visualise the whole needle trajec-
tory, resulting in longer procedure times and more radiation
exposure to the patient. Because of the long needle trajectory,
the needle passes different soft tissues with different resis-
tance; this, in combination with respiratory movement, adds
more complexity to the procedure [21].
For angulated procedures, MRI also offers a good alter-
native to a needle intervention, especially for lesions invis-
ible on CT and US. Stattaus et al. [22] reported a sensitivity
of 95.5%, specificity of 100%, and an accuracy of 96%
using a short, wide-bore 1.5 T MR system. Kühn et al.
[23] reported an accuracy of 94%. Both groups agree that
MR-guided procedures are also feasible for lesions with
quite a steep angulation due to MRI’s capacity for multi-
planar viewing. However, they acknowledge that the gantry
size in regular MR systems is limited. Other possible dis-
advantages of MR-guided procedures include that they are
considered expensive because of dedicated materials and
biopsy systems, the reported mean procedure time is 42–
48 min (compared to our 29 min), and needle artifacts may
be present.
In our experience steep, double-angulation procedures
are easier with CBCT guidance because of the C-arm ge-
ometry with an angulation range up to 50°. In addition to
this, there is real-time feedback of the fluoroscopy with a
large field-of-view compared to CT fluoroscopy. Breathing
can be halted at a point where the diaphragm on the fluo-
roscopy image exactly matches the diaphragm in the (dou-
ble oblique) overlay slice of the cone-beam CT. This enables
real-time compensation of breathing movements during the
progression of the needle, compensating for the respiratory
movement and deviation due to different tissue resistance.
Therefore, in our experience, CBCT guidance is better for
biopsying hard-to-reach lesions than CT or MRI.
The two nondiagnostic lesions presented normal kidney
parenchyma with atypical cells, but the biopsies were found
to be insufficient for diagnosis in the histopathological re-
port. Because of this report and the malignant features on
abdominal imaging with CT, the decision was made to
perform a (partial) nephrectomy. Both of these lesions were
exophytic. The definite diagnosis in both patients was a
renal cell carcinoma. Checking with the control CBCT, it
appears that the biopsies were most likely planned slightly
peripheral to the lesions. That is a possible reason for the
presence of at least some atypical cells in the specimen
suggesting a malignancy, but there was not enough material
to make a definitive conclusion.
The comparable results of CBCT guidance and the liter-
ature suggest that this new technique can be performed
easily and accurately, but it is not as widely available as
CT, ultrasound, or MRI.
Using the reported conversion factor from DAP to effec-
tive dose of 0.28–0.29 (mSv·Gy−1·cm−2) by Suzuki et al.
[24] during abdominal cone-beam CT, our mean effective
dose was 12.5 (± 5.9 SD) mSv. This conversion was done to
compare the dose of CBCT guidance to CT guidance in the
literature. Tsalafoutas et al. [25] report an effective dose of
23 mSv during conventional CT-guided biopsies in which
unenhanced, intervention, and control post-procedure CT
data acquisitions were performed. Other studies report a
lower effective dose (7.1–12 mSv) during CT-guided biop-
sies; however in these procedures no final post-procedure
CT data acquisition was performed to check for possible
complications [26, 27].
No serious complications occurred during our proce-
dures. The literature on renal mass biopsy shows complica-
tions of pain, hematuria, bleeding, and tumor seeding. The
percentage of complications depends on the size of the
needle [28, 29]. Vaseduvan et al. [1] used a 16 G needle
and reported a complication rate in 100 biopsies of 1%, for
which the patient needed a blood transfusion. Nadal et al.
[12] reported a complication rate of 12% in biopsy of renal
masses using an 18 G biopsy needle. In this report 3% of the
procedures needed a blood transfusion. In the report of
Whittier et al. [30], a 13% overall complication rate was
reported using a 14 G biopsy needle. Fifty percent of these
were major complications (e.g., gross hematuria, death). In
our population we had one patient (2.4%) with some persis-
tent bleeding out of the co-axial needle (17 G), which could
be directly treated. No other complications or tumor seeding
along the needle track was noticed during the follow-up.
A limitation of this study is the inability to obtain a
definitive confirmation of the lesions defined as nonmalig-
nant (except the two non-diagnostic lesions with suspicious
cells which were operated), e.g., organising hematoma,
pseudotumor, and the three nondiagnostic results, because
all were treated conservatively. However, no changes on
subsequent CT indicating malignancy (e.g., increasing size)
were noted during follow-up, and therefore the definitive
diagnosis was assumed to be benign. A second possible
limitation is our relatively short follow-up period of 2 years.
A new image-merging feature has recently been introduced
into the planning system (XperGuide®, Philips Healthcare, the
Netherlands). This tool allows recent cross-sectional DICOM
data (CTor MRI) to be used to plan the needle trajectory. After
importing these data into the system, a match is mademanually
between the recent DICOM data and the (low-dose) cone-
beam CT data. Preliminary experimental results of this merg-
ing feature for accurate planning are promising, possibly lead-
ing to even higher accuracy, especially in endophytic masses.
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In conclusion, our results demonstrate acceptable sensitiv-
ity and accuracy of renal mass needle biopsy using 3D CBCT
guidance. CBCT guidance appears to be a safe and accurate
procedure for biopsy of small (<4 cm) renal masses, especially
those in difficult-to-reach anatomical regions.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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